The landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.
Binbin Zheng-Lin, MD, MSc
Articles by Binbin Zheng-Lin, MD, MSc
The landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.